[go: up one dir, main page]

DE602004020812D1 - Neue zwischenprodukte für linezolid und verwandte verbindungen - Google Patents

Neue zwischenprodukte für linezolid und verwandte verbindungen

Info

Publication number
DE602004020812D1
DE602004020812D1 DE602004020812T DE602004020812T DE602004020812D1 DE 602004020812 D1 DE602004020812 D1 DE 602004020812D1 DE 602004020812 T DE602004020812 T DE 602004020812T DE 602004020812 T DE602004020812 T DE 602004020812T DE 602004020812 D1 DE602004020812 D1 DE 602004020812D1
Authority
DE
Germany
Prior art keywords
fluoro
linezolid
morpholinyl
related compounds
intermediate products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004020812T
Other languages
English (en)
Inventor
Rao Mohan
Reddy Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symed Labs Ltd
Original Assignee
Symed Labs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35784913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004020812(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symed Labs Ltd filed Critical Symed Labs Ltd
Publication of DE602004020812D1 publication Critical patent/DE602004020812D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004020812T 2004-07-20 2004-07-20 Neue zwischenprodukte für linezolid und verwandte verbindungen Expired - Lifetime DE602004020812D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000218 WO2006008754A1 (en) 2004-07-20 2004-07-20 Novel intermediates for linezolid and related compounds

Publications (1)

Publication Number Publication Date
DE602004020812D1 true DE602004020812D1 (de) 2009-06-04

Family

ID=35784913

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004020812T Expired - Lifetime DE602004020812D1 (de) 2004-07-20 2004-07-20 Neue zwischenprodukte für linezolid und verwandte verbindungen

Country Status (7)

Country Link
US (1) US7429661B2 (de)
EP (1) EP1768967B1 (de)
AT (1) ATE429423T1 (de)
DE (1) DE602004020812D1 (de)
ES (1) ES2325401T3 (de)
PL (1) PL1768967T3 (de)
WO (1) WO2006008754A1 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2803516T3 (es) 2003-10-16 2021-01-27 Symed Labs Ltd Una forma cristalina de linezolid
ES2294494T3 (es) * 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
AU2007266535A1 (en) 2006-05-31 2007-12-06 Abbott Laboratories Thiazole compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
EP2024349B1 (de) 2006-05-31 2017-08-02 AbbVie Inc. Verbindungen als cannabinoid-rezeptorliganden und ihre verwendung
CA2681586A1 (en) 2007-03-28 2008-10-09 Abbott Laboratories 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
MX2009012374A (es) 2007-05-18 2009-12-01 Abbott Lab Compuestos novedosos como ligandos del receptor de canabinoides.
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009114566A1 (en) 2008-03-11 2009-09-17 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
US8173687B2 (en) 2008-08-15 2012-05-08 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8846730B2 (en) 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
RU2011115087A (ru) 2008-09-16 2012-10-27 Эбботт Лэборетриз (Us) Замещенные бензамиды в качестве лигандов каннабиноидного рецептора
EP2352726A1 (de) 2008-10-17 2011-08-10 Abbott Laboratories Trpv1-antagonisten
MX2011004090A (es) 2008-10-17 2011-05-31 Abbott Lab Antagonistas trpv1.
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101692705B1 (ko) 2008-12-05 2017-01-04 애브비 인코포레이티드 암 및 면역 질환의 치료를 위한 Ｂｃｌ­２­선택적 아폽토시스-유도제로서의 설폰아미드 유도체
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PA8854001A1 (es) 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
CN101774978B (zh) * 2009-01-13 2011-09-21 联化科技股份有限公司 一种利奈唑胺的制备方法及其中间体
RU2538965C2 (ru) 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
PT2511264E (pt) 2009-01-19 2015-07-17 Abbvie Inc Agentes indutores de apoptose destinados ao tratamento de cancro e de doenças imunes e autoimunes
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
EP2411371B1 (de) 2009-03-27 2015-05-20 AbbVie Inc. Verbindungen als cannabinoidrezeptorliganden
WO2010111572A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8288428B2 (en) 2009-03-27 2012-10-16 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2243479A3 (de) 2009-04-20 2011-01-19 Abbott Laboratories Neuartige Amid- und Amidinderivate und deren Verwendungen
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2944638A1 (de) 2009-05-26 2015-11-18 AbbVie Bahamas Limited Apoptoseinduktoren zur behandlung von krebs sowie von immun- und autoimmunerkrankungen
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8962639B2 (en) 2009-05-29 2015-02-24 Abbvie Inc. Potassium channel modulators
WO2011053740A1 (en) 2009-10-28 2011-05-05 Belkin International, Inc. Portable multi-media communication device protective carrier and method of manufacture therefor
EP2504317A1 (de) 2009-11-25 2012-10-03 Abbott Laboratories Kaliumkanalmodulatoren
TW201130855A (en) 2009-12-16 2011-09-16 Abbott Lab Prodrug compounds useful as cannabinoid ligands
US20130137864A1 (en) * 2009-12-26 2013-05-30 Jayaraman Venkat Raman Process for the preparation of linezolid
ES2553143T3 (es) 2010-03-25 2015-12-04 Abbvie Inc. Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunitarias y autoinmunitarias
KR20130108975A (ko) 2010-04-30 2013-10-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 리네졸리드의 제조 방법
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN102311400A (zh) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
JP2013538800A (ja) 2010-08-10 2013-10-17 アッヴィ・インコーポレイテッド 新規ｔｒｐｖ３モジュレーター
CN103140487A (zh) 2010-08-11 2013-06-05 斯索恩有限公司 制备利奈唑胺的方法
EP2690100A1 (de) 2010-08-11 2014-01-29 Synhton B.V. Verfahren zur Linezpolid Herstellung
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2012032533A2 (en) 2010-09-07 2012-03-15 Symed Labs Limited Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl} morpholin-3-one
JP5998142B2 (ja) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6068352B2 (ja) 2010-10-29 2017-01-25 アッヴィ・インコーポレイテッド アポトーシス誘発剤を含む固体分散体
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
CN103347860A (zh) 2010-11-15 2013-10-09 Abbvie公司 Nampt抑制剂
BR112013012078A2 (pt) 2010-11-15 2019-09-24 Abbvie Inc inibidores de nampt e rock
WO2012067824A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Potassium channel modulators
WO2012067822A1 (en) 2010-11-16 2012-05-24 Abbott Laboratories Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
CA2817629C (en) 2010-11-23 2019-08-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
SI2595968T1 (sl) 2011-02-24 2016-01-29 Lee Pharma Limited Novi postopek za pripravo linezolida in njegovih novih intermediatov
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US9012651B2 (en) 2011-03-24 2015-04-21 Abbvie Inc. TRPV3 modulators
JP5934778B2 (ja) 2011-03-25 2016-06-15 アッヴィ・インコーポレイテッド Ｔｒｐｖ１拮抗薬
WO2012140061A1 (en) * 2011-04-11 2012-10-18 Sandoz Ag Method for the preparation of substituted oxazolidinones
CN102229577A (zh) * 2011-05-11 2011-11-02 石药集团中诺药业（石家庄）有限公司 利奈唑胺中间体的制备及纯化方法
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
CN102304125B (zh) * 2011-07-05 2014-02-19 浙江亚太药业股份有限公司 一种用于制备利奈唑胺的中间体
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013098833A2 (en) 2011-09-08 2013-07-04 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
TWI561521B (en) 2011-10-14 2016-12-11 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
US8772499B2 (en) 2011-10-24 2014-07-08 Abbvie Inc. TRPV3 modulators
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103103229B (zh) * 2011-11-15 2015-03-18 安琪酵母股份有限公司 一种利奈唑酮中间体的合成方法
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013149376A1 (en) 2012-04-02 2013-10-10 Abbott Laboratories Chemokine receptor antagonists
CN104334526A (zh) 2012-04-20 2015-02-04 艾伯维公司 异吲哚酮衍生物
CN104271572A (zh) 2012-05-11 2015-01-07 艾伯维公司 用作nampt抑制剂的噻唑羧酰胺衍生物
WO2013170113A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
WO2013170115A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
HK1208221A1 (en) 2012-05-11 2016-02-26 Abbvie Inc. Nampt inhibitors
US20130317054A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US20130317055A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
CN103420933B (zh) * 2012-05-26 2016-03-02 鲁南制药集团股份有限公司 一种利奈唑胺的制备方法
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103570639B (zh) * 2012-08-08 2016-02-03 成都国弘医药有限公司 一种利奈唑胺的合成方法
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
WO2014041131A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
CN102887871B (zh) * 2012-09-26 2015-12-02 苏州敬业医药化工有限公司 3-取代苯基-5-氨甲基噁唑烷-2-酮的制备方法
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid
CA2901334A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Pyridine cdk9 kinase inhibitors
WO2014159999A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
WO2014139328A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
CN105189512A (zh) 2013-03-14 2015-12-23 艾伯维公司 吡咯并嘧啶cdk9激酶抑制剂
WO2014141067A2 (en) * 2013-03-14 2014-09-18 Benova Labs Pvt Limited Process for the preparation of oxazolidinone derivatives
JP2016510788A (ja) 2013-03-14 2016-04-11 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ホスホジエステラーゼ１０ａ型の新規な阻害剤化合物
CN105339366A (zh) 2013-03-14 2016-02-17 艾伯维德国有限责任两合公司 带有取代的氧杂环丁烷的2-吲哚酮衍生物及其治疗血管加压素相关疾病的用途
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2015012896A (es) 2013-03-14 2016-06-02 Abbvie Inc Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014174522A1 (en) * 2013-04-25 2014-10-30 Symed Labs Limited Improved processes for the preparation of linezolid using novel intermediates
MX2016004934A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2016004936A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia.
US9840495B2 (en) 2013-12-20 2017-12-12 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
US9328112B2 (en) 2014-02-06 2016-05-03 Abbvie Inc. Tetracyclic CDK9 kinase inhibitors
WO2015173392A1 (en) 2014-05-15 2015-11-19 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a co-bound spiro substituent and use thereof for treating vasopressin-related diseases
CN105315231A (zh) * 2014-06-11 2016-02-10 成都自豪药业有限公司 利奈唑胺相关物质的制备方法
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US20180243298A1 (en) 2015-04-02 2018-08-30 Abbvie Inc. Trpv3 modulators
EP3380483A1 (de) 2015-11-25 2018-10-03 Abbvie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- oder -pyridooxazepine mit einem sauerstoffhaltigen substituenten und verwendung bei der behandlung von 5-ht2c-abhängigen erkrankungen
CN105566242B (zh) * 2016-01-12 2017-12-05 江苏豪森药业集团有限公司 利奈唑胺及其中间体的制备方法
US9643939B1 (en) 2016-04-18 2017-05-09 Optimus Drugs Private Limited Process for the preparation of linezolid
USRE47606E1 (en) 2016-04-21 2019-09-17 Optimus Drugs Private Limited Process for the preparation of linezolid
KR101832115B1 (ko) * 2016-04-21 2018-02-23 옵티머스 드럭스 피브이티 리미티드 리네졸리드를 제조하는 개선된 방법
JP6927548B2 (ja) 2016-05-07 2021-09-01 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド ある種のタンパク質キナーゼ阻害剤
CN110139857B (zh) 2016-11-28 2023-07-21 重庆复尚源创医药技术有限公司 作为吲哚胺2,3-双加氧酶抑制剂的亚砜亚胺、磺酰亚胺酰胺、磺酰二亚胺和二酰亚胺磺酰胺化合物
WO2018175449A1 (en) 2017-03-21 2018-09-27 AbbVie Deutschland GmbH & Co. KG Proline amide compounds and their azetidine analogues carrying a specifically substituted benzyl radical
WO2018192462A1 (en) 2017-04-18 2018-10-25 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptosis-inducing agents
EP3765462B1 (de) 2018-03-14 2023-10-18 Fochon Biosciences, Ltd. Substituierte (2-azabicyclo [3.1.0] hexan-2-yl)pyrazolo[1, 5-a]pyrimidin- und imidazo [1, 2-b] pyridazin-verbindungen als trk-kinasehemmer
AU2019236892B2 (en) 2018-03-23 2023-12-14 Fochon Pharmaceuticals, Ltd. Deuterated compounds as ROCK inhibitors
CN109232457A (zh) * 2018-03-26 2019-01-18 华夏生生药业(北京)有限公司 一种利奈唑胺的制备方法
CN108892663A (zh) * 2018-08-10 2018-11-27 泰州申合泰尔生物医药有限公司 一种合成利伐沙班的中间体、合成方法和用途
WO2021184339A1 (en) 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
CN113045509B (zh) * 2021-06-01 2021-10-22 上海翰森生物医药科技有限公司 利奈唑胺的工业生产方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2810349A1 (de) * 1978-03-10 1979-09-20 Kali Chemie Pharma Gmbh Verfahren zur herstellung von 3-hydroxy-6-phenyl-1,2,3,4-tetrahydro- 1,5-benzodiazocinen
FR2506769A2 (fr) * 1978-06-09 1982-12-03 Delalande Sa Para-((cyano-5 n pentyl-1) phenyl)-3 methoxymethyl-5 oxazolidinone-2, son procede de preparation et ses applications en therapeutique
US4340606A (en) * 1980-10-23 1982-07-20 E. I. Du Pont De Nemours And Company 3-(p-Alkylsulfonylphenyl)oxazolidinone derivatives as antibacterial agents
FR2608604B1 (fr) 1986-12-19 1989-04-28 Delalande Sa Derives 5-hydroxyethyles de l'oxazolidinone-2, leurs procedes de preparation et leurs applications en therapeutique
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CZ298060B6 (cs) 1996-04-11 2007-06-06 Pharmacia & Upjohn Company Zpusob prípravy oxazolidinonu
ATE359994T1 (de) 1997-11-07 2007-05-15 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von oxazolidinonen
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10105989A1 (de) * 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN1155585C (zh) 2001-12-19 2004-06-30 中国医学科学院医药生物技术研究所 3,5－取代噁唑烷酮衍生物及其制备方法和应用
ES2294494T3 (es) * 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.

Also Published As

Publication number Publication date
US20060247435A1 (en) 2006-11-02
US7429661B2 (en) 2008-09-30
EP1768967B1 (de) 2009-04-22
ES2325401T3 (es) 2009-09-03
EP1768967A1 (de) 2007-04-04
PL1768967T3 (pl) 2009-09-30
WO2006008754A1 (en) 2006-01-26
ATE429423T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
ATE429423T1 (de) Neue zwischenprodukte für linezolid und verwandte verbindungen
WO2005099353A3 (en) A novel process for the preparation of linezolid and related compounds
Apfel et al. Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents
AU2010242496B2 (en) Processes for the preparation of Rivaroxaban and intermediates thereof
Desvergnes et al. Total synthesis of (+)-hyacinthacine A2 based on SmI2-induced nitrone umpolung
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
ZA200603942B (en) Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
CA2434937A1 (en) Phenyl derivatives
GB0315966D0 (en) Compounds
CZ20031799A3 (cs) Nové heterocyklické sloučeniny s antibakteriálním účinkem, způsob jejich výroby a farmaceutické kompozice s jejich obsahem
SI2824100T1 (en) 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
EA201391647A1 (ru) Способ получения ривароксабана и промежуточные соединения, получаемые в указанном способе
Colpaert et al. Asymmetric synthesis of α-chloro-β-amino-N-sulfinyl imidates as chiral building blocks
Bhattarai et al. Synthesis and in vitro evaluation of the antitubercular and antibacterial activity of novel oxazolidinones bearing octahydrocyclopenta [c] pyrrol-2-yl moieties
Carroccia et al. Straightforward access to 4-membered sulfurated heterocycles: introducing a strategy for the single and double functionalization of thietane 1-oxide
CA2449578A1 (en) Pyrrolidine oxadiazole- and thiadiazole derivatives
GEP20063896B (en) New heterocyclic oxime compound, method for production of the same and pharmaceutical composition comprising the same
ATE543805T1 (de) Verfahren zur herstellung von oxazolidinonderivaten
KR20070027614A (ko) 항박테리아제로서의3-[4-(6-｛4,5-디히드로이속사졸-3-일｝피리딘-3-일)-3-페닐]-5-(1ｈ-1,2,3-트리아졸-1-일메틸)-1,3-옥사졸리딘-2-온
Pancholi et al. Asymmetric Synthesis of 2-Substituted Azetidin-3-ones via Metalated SAMP/RAMP Hydrazones
JPWO2021050824A5 (de)
CN1136810A (zh) 5-芳基异噁唑-4-基-取代的2-氨基羧酸化合物
Li et al. An approach to the anticoagulant agent rivaroxaban via an isocyanate-oxirane cycloaddition promoted by MgI2. etherate
DE602005015223D1 (de) 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-on-derivate und verwandte verbindungen zur behandlung von erkrankungen des zentralnervensystems
Hazelden Development of new classes of aza-Heck cyclisation for the synthesis of nitrogen heterocycles

Legal Events

Date Code Title Description
8364 No opposition during term of opposition